Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors

Clinical Cancer Research

Volumn 20, Issue 5, 2014, Pages 1212-1222

  Valentino, Joseph D ^a,c   Li, Jing ^a,c   Zaytseva, Yekaterina Y ^a,c   Mustain, W Conan ^a,c   Elliott, Victoria A ^a   Kim, Ji Tae ^a,c   Harris, Jennifer W ^a,c   Campbell, Katherine ^a,c   Weiss, Heidi ^a,c   Wang, Chi ^a,c   Song, Jun ^a,c   Anthony, Lowell ^b,c   Townsend Jr, Courtney M ^d   Evers, B Mark ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPARLISIB; DACTOLISIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NEUROTENSIN; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOID; CELL PROLIFERATION; CELLULAR SECRETION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CARCINOID; MALE; MONOTHERAPY; MOUSE; NEUROSECRETORY CELL; NONHUMAN; PANCREAS CANCER; PANCREATIC CARCINOID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

AMINOPYRIDINES; ANIMALS; APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHENYLAMINE; DRUG SYNERGISM; HUMANS; IMIDAZOLES; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; NEUROENDOCRINE TUMORS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); QUINOLINES; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895787003     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1897     Document Type: Article

References (35)

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-59.
2. KulkeMH. Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin North Am 2007;21:433-55.
3. Valentino J, Evers BM. Recent advances in the diagnosis and treatment of gastrointestinal carcinoids. Adv Surg 2011;285-300.
4. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005;89:151-60.
5. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-7.
6. Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, Qiu S, et al. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res 2009;15: 7207-16.
7. Silva SR, Zaytseva YY, Jackson LN, Lee EY, Weiss HL, Bowen KA, et al. The effect of PTEN on serotonin synthesis and secretion from the carcinoid cell line BON. Anticancer Res 2011;31:1153-60.
8. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62.
9. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
10. Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg 2006; 243:833-42.
11. Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, Xiao SY, et al. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci U S A 2008;105: 20315-20.
12. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
13. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263-84.
14. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30.
15. Zitzmann K, Ruden J, Brand S, Goke B, Lichtl J, Spottl G, et al. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 2010;295:100-9.
16. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, et al. 4EBP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010;18:39-51.
17. Valentino JD, Elliott VA, Zaytseva YY, Rychahou PG, Mustain WC, Wang C, et al. Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer. Surgery 2012;152: 277-85.
18. Tannapfel A, Vomschloss S, Karhoff D, Markwarth A, Hengge UR, Wittekind C, et al. BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. Am J Clin Pathol 2005; 123:256-60.
19. Akiyama H, Kamiguchi H. Phosphatidylinositol 3-kinase facilitates microtubule-dependent membrane transport for neuronal growth cone guidance. J Biol Chem 2010;285:41740-8.
20. Li J, Song J, Cassidy MG, Rychahou P, Starr ME, Liu J, et al. PI3K p110alpha/Akt signaling negatively regulates secretion of the intestinal peptide neurotensin through interference of granule transport. Mol Endocrinol 2012;26:1380-93.
21. Evers BM, Townsend CMJr, Upp JR, Allen E, Hurlbut SC, KimSW, et al. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 1991; 101:303-11.
22. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989;246:491-4.
23. Brandt DW, Pandol SJ, Deftos LJ. Calcium-stimulated parathyroid hormone-like protein secretion: potentiation through a protein kinase-C pathway. Endocrinology 1991;128:2999-3004.
24. Doihara H, Nozawa K, Kojima R, Kawabata-Shoda E, Yokoyama T, Ito H. QGP-1 cells release 5-HT via TRPA1 activation: a model of human enterochromaffin cells. Mol Cell Biochem 2009;331:239-45.
25. Rychahou PG, Murillo CA, Evers BM. Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNFrelated apoptosis-inducing ligand (TRAIL). Surgery 2005;138:391-7.
26. Li J, O'Connor KL, Cheng X, Mei FC, Uchida T, Townsend CM Jr, et al. Cyclic adenosine 50-monophosphate-stimulated neurotensin secretion is mediated through Rap1 downstream of both Epac and protein kinase A signaling pathways. Mol Endocrinol 2007;21: 159-71.
27. Li J, Chen LA, Townsend CM Jr, Evers BM. PKD1, PKD2, and their substrate Kidins220 regulate neurotensin secretion in the BON human endocrine cell line. J Biol Chem 2008;283:2614-21.
28. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-74.
29. Pitt SC, Davis R, Kunnimalaiyaan M, Chen H. AKT and PTEN expression in human gastrointestinal carcinoid tumors. Am J Transl Res 2009;1:291-9.
30. Voortman J, Lee JH, Killian JK, Suuriniemi M, Wang Y, Lucchi M, et al. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A 2010;107:13040-5.
31. Wang L, Ignat A, Axiotis CA. Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol 2002;10:139-46.
32. Pitt SC, Chen H, Kunnimalaiyaan M. Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors. Ann Surg Oncol 2009;16:2936-42.
33. Pitt SC, Chen H, Kunnimalaiyaan M. Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. J Am Coll Surg 2009;209: 82-8.
34. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP, Caplin ME. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol 2006;18:355-60.
35. Modlin IM, Shapiro MD, Kidd M. Carcinoid tumors and fibrosis: an association with no explanation. Am J Gastroenterol 2004;99: 2466-78.